| 摘要: |
| ［摘要］ 目的 探讨聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎的近期与远期疗效。方法 将38例患者随机分为治疗组20例，用聚乙二醇干扰素α-2a 180 μg皮下注射，每周1次，联合口服利巴韦林500 mg，3次/d，疗程共48周。对照组18例，肌肉注射IFN 300万U，3次/周,联合口服利巴韦林500 mg，3次/d,疗程共48周。结果 治疗组治疗后第12、24及48周患者的ALT复常率分别为45.0%、80.0%、95.0%，对照组分别为38.9%、61.0%和66.7%；HCV-RNA在治疗12、24、48周时阴转率治疗组分别为25.0%、70.0%和80.0%，对照组分别为22.2%、50.0%、77.8%；治疗组与对照组组内比较不同时点差异均有统计学意义（P<0.05或P<0.01）；组间比较治疗后48周HCV-RNA转阴率差异无统计学意义(P>0.05)，ALT复常率比较差异有统计学意义（P<0.05)。结论 聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎的近期与远期疗效均较好，在降低转氨酶方面也优于IFN联合利巴韦林，且用药方便，患者依从性好。 |
| 关键词: 慢性丙型肝炎 聚乙二醇干扰素α-2a 干扰素 利巴韦林 |
| DOI：10.3969/j.issn.1674-3806.2011.03.17 |
| 分类号:R 512.6 |
| 基金项目: |
|
| Clinical analysis of pegylated α-2a combined with ribavirin in the treatment of chronic hepatitis C |
|
LUO Xiao-xia
|
|
Department of Gastroenterology，Sanxiang People′s Hospital of Zhongshan，Guangdong 528463，China
|
| Abstract: |
| ［Abstract］ Objective To investigate the short-term and long-term therapeutic effects of pegylated-interferon α-2a combined with ribavirin in the treatment of chronic hepatitis C.Methods All patients were randomly divided into two groups. In the treatment group 20 patients were treated with pegylated interferon α-2a 180 μg subcutaneously, 1 time/week, for 48 weeks, combined with oral ribavirin 500 mg tid, followed up for 2 years. In the control group, 18 patients, with injection of IFNa-2b, 300 MU, 3 times/week. Oral ribavirin 500 mg tid. Treatment period lasted 48 weeks.Results 12,24 and 48 weeks after treatment, ALT normalization rate in the treatment group were 45.0%, 80.0%, 95.0% respectively. Those in the control group were 38.90%,61% and 66.7% respectively HCV-RNA negative conversion rates in the control group were 22.2% and 50.0%, 77.8%, those in the treatment group were 25.0%, 70.0% and 80.0% respectively within group comparison showed there were significant differences in the two groups. After 48 weeks, HCV-RNA conversion rate was no significant statistical difference between two groups (P> 0.05). After 48 weeks the ALT normalization rates between treatment group and control group were significantly different (P<0.05).Conclusion The short-term and long-term therapeutic effects of pegylated-interferon α-2a combined with ribavirin in treating patients with chronic hepatitis C were good. It is better than IFN combined with ribavirin in reducing aminotransferase, treatment convenience and patient compliance is good. |
| Key words: Chronic hepatitis C Pegylated interferon α-2a IFN Ribavirin |
